A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).
Sponsor: AstraZeneca AB
Phase: 3
Disease: Newly diagnosed multiple myeloma
EU trial number: 2025-524014-29-00
Population: Adults with documented, measurable newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation as initial therapy, have adequate organ function for CAR-T-cell treatment, and are candidates for IsaVRd or DRd induction.
Register Investigator Interest
Interested in offering this trial to suitable patients?